Douglas E. Williams is the executive vice president of R&D at Biogen Idec. Previously, he was CEO of ZymoGenetics. He joined ZymoGenetics in 2004 as Chief Scientific Officer and Executive Vice President overseeing the company's research and development programs, and was promoted to President in July 2007. Dr. Williams has held senior level positions at a number of notable biotechnology companies, including Seattle Genetics, Immunex, Amgen and Genesis Research and Development, a New Zealand based biotechnology company. As Executive Vice President and Chief Technology Officer at Immunex, Dr. Williams played a significant role in the discovery and early development of Enbrel. In addition, Dr. Williams was a member of Immunex's Board of Directors. Before entering the biotechnology industry, Dr. Williams served on the faculty of the Indiana University School of Medicine and worked at the Roswell Park Memorial Institute. Dr. Williams earned a B.S. magna cum laude in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo.